From fast-tracked clinical trials to emergency medical devices and telehealth innovations, the Life Sciences sector is providing solutions to Covid-19. This series of reports explores what risks organisations are entering into as they ride to the world’s rescue and how they can protect themselves
With the scientific community throwing everything it has at Covid-19, best practice is slipping in clinical trials. What trade-offs are being made and who is liable?
Emerging risks in Covid-19 clinical trials
|
Genomics has provided us with a new armoury for tackling pandemics, enabling us to respond faster and with more accuracy to COVID-19. Behind the scenes it is also gradually redefining healthcare, ushering in a more predictive and personalised approach, with potentially big implications for drug company liability.
|
Learn more about how Masterpackage can respond to your clients' specific exposures